TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: GI consult rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CDE rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to GI consult and CDE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease progression
Endpoint domain: Mortality/survival
Primary endpoint: Vestibulo-ocular reflex gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dizziness Handicap Inventory mean total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Favorable neurologic outcome (CPC 1 or 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tibial distal motor latencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximal HR induced by cross‐linking anti‐IgE antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intrinsic basophil sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time required to suture the uterine wall defect
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: Degree of surgical difficulty
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: Number of flushes per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of allogenic transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of reactions
Endpoint domain: Adverse events/effects
Primary endpoint: 1-hour CCI after transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 20-hour CCI after transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Raised ICP episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: development of large motor ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of fine movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of language
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of social behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean daily narcotic requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attempts to receive patient-controlled analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Earlier ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate-specific antigen (PSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement in diagnostic performance for skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Evaluation planning for malignant melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Evaluation planning for squamous cell carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Implementation and acceptability of the ACS QUIK toolkit intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anti-PRP concentration ≥0.15 μg/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-diphtheria concentration ≥0.01 IU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-tetanus concentration ≥0.01 IU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Significant arrhythmic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cusp fracture resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of antipsychotic medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower oesophageal sphincter pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: transient lower oesophageal sphincter relaxation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean myocardial retention fraction of EPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Corrected tracer retention fractions of EPI and HED
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean difference in IPSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial vaginosis prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in Nugent score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Log concentration of G vaginalis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ventilator-associated pneumonia (VAP)
Endpoint domain: Adverse events/effects
Primary endpoint: Biofilm culture positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Composite of cardiovascular death and unplanned hospitalization for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Global evaluation improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in psoriasis severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of stunting (HAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of wasting (WHZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Deviation development (PSDQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale for nasal crusting, nasal congestion, and foul odor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SNOT scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IRLS total score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-I responders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: arterial thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean VAT area changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative VAT losses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decreases in SAT areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nausea and vomiting scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Allograft rejection with hemodynamic compromise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inconvenience of drainage tubes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VAS ratings of inconvenience and discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Preference for tube system
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Atelectatic area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lung ultrasound scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional status at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean total symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: psychotic and depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete relief of itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete relief of scaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure reduction ≥50% from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Carer burden scale reduction
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Percentage agreement levels between fitting techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual performance and lens comfort comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suitability of Fitscan-derived lenses for dispensing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hard endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: average serum testosterone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: tolerability of 11β‐MNTDC
Endpoint domain: Adverse events/effects
Primary endpoint: improvements in pain measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: odds of cigarette smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occasions of drunkenness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of sexual partners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: latency period from rupture to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arrival time into the postoperative care unit
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: desire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychological arousal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall sexual functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Criterion validity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choroidal Blood Flow (ChBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of reflux events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Geometric mean number of TLESRs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Geometric mean LES pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Arousal success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of treatment failures
Endpoint domain: Adverse events/effects
Primary endpoint: side effects experienced
Endpoint domain: Adverse events/effects
Primary endpoint: Sexual function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Circulating levels of sGP130 or sIL-6r
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in glycated hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean change in SKAMP-Combined score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food Intake (FI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Growth Hormone (GH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adequate use of AST
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Median time-to-ON
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients turned ON at 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death from cardiovascular causes or hospitalization for HF
Endpoint domain: Mortality/survival
Primary endpoint: Baseline tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite anxiety score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ratio of serum total antioxidant capacity to malondialdehyde
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serotype-specific antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: quit attempt (no smoking for at least 24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital admissions for cardiovascular events
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Median time to absolute neutrophil count > or = 500/microL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Median time to platelet count greater than 20,000/microL untransfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Median time to RBC transfusion independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: low-density lipoprotein cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: thermal saving of closed circuit anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in average RNFL thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: rate of symptoms relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-fold increase in titer to at least 2 antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 4-fold increase in titer to at least 2 antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: failure to show a 2-fold response to any antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Endoscopic healing rates for gastric and duodenal ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative recurrence rates at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SAnB (Sulcus Bleeding Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RQLQ scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work productivity improvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Daily symptom scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morbidity (fever, symptomatic UTI, hematuria)
Endpoint domain: Adverse events/effects
Primary endpoint: Inhibition of wheal and flare response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Episodes of bradycardia and hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Number of gadolinium-enhancing lesions affecting the cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent AT/AF
Endpoint domain: Mortality/survival
Primary endpoint: Mood swings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of mood episodes
Endpoint domain: Mortality/survival
Primary endpoint: MTX plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time during which MTX plasma concentrations exceeded 0.1 microM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of harvested LNs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diameter of LNs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of stained LNs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid levels
Primary endpoint: HMG-CoA reductase gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDLR gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to development of severe mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily AI drug requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Performance in letter-number sequencing subtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scar-appearance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved scar-texture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of death from disease of the circulatory system
Endpoint domain: Mortality/survival
Primary endpoint: risk of death from heart disease
Endpoint domain: Mortality/survival
Primary endpoint: Use of involuntary treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: IL-1β/IL-1ra levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Compliance with initial invitation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average cost per partner treated
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effectiveness at treating partners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in PPI-VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Roland Morris disability score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Second stage of labor duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Displacement of injected sperm suspension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Point prevalence of Chronic Fatigue Syndrome (CFS)
Endpoint domain: Mortality/survival
Primary endpoint: 1-year incidence of Chronic Fatigue Syndrome (CFS)
Endpoint domain: Mortality/survival
Primary endpoint: New COPD cases identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficulties during quit attempts
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Side effects of smoking cessation medications
Endpoint domain: Adverse events/effects
Primary endpoint: Transition to psychosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission from UHR status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total mean symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of ERPs to modified vs unmodified images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone quantitative ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma FSH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: plasma estradiol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean number of lower respiratory tract illnesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean number of antibiotic courses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean number of days ill
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: physical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liveliness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: postmeal blood glucose AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: insulin AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: food intake suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant hypoxaemia (desaturation by > or = 5% to < 90%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increase in number of glaucoma medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 2-hour MBS freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local failure (LF) rate
Endpoint domain: Mortality/survival
Primary endpoint: Blood drug concentrations of temsirolimus and sirolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative number of units of RBCs transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Final Hct concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: severity of depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite outcome of recurrent venous thromboembolism or major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: total sleep duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: PISQ total score changes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status